Cargando…
Prognostic Value of the Pace of Tumor Progression as Assessed by Serial (18)F-FDG PET/CT Scan and Liquid Biopsy in Refractory Colorectal Cancer: The CORIOLAN Trial
SIMPLE SUMMARY: Management of chemorefractory colorectal cancer patient is challenging, and reliable tools which can predict individual patient prognosis and help the decision making are needed. In this study, we hypothesized that the natural pace of cancer growth and progression, as assessed by ear...
Autores principales: | Camera, Silvia, Akin Telli, Tugba, Woff, Erwin, Vandeputte, Caroline, Kehagias, Pashalina, Guiot, Thomas, Critchi, Gabriela, Wissam, Yacine, Bregni, Giacomo, Trevisi, Elena, Pretta, Andrea, Senti, Chiara, Leduc, Sophia, Gkolfakis, Paraskevas, Hoerner, Frédéric, Rothé, Françoise, Sclafani, Francesco, Flamen, Patrick, Deleporte, Amelie, Hendlisz, Alain |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601470/ https://www.ncbi.nlm.nih.gov/pubmed/32987838 http://dx.doi.org/10.3390/cancers12102752 |
Ejemplares similares
-
Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient’s outcome in advanced colorectal cancer: the CORIOLAN study
por: Deleporte, Amelie, et al.
Publicado: (2014) -
Regorafenib assessment in refractory advanced colorectal cancer: RegARd-C study protocol
por: Hendlisz, Alain, et al.
Publicado: (2015) - Symphony No. 6 ; Coriolan, Egmont
-
Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance
por: Kehagias, Pashalina, et al.
Publicado: (2022) -
Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer
por: Woff, Erwin, et al.
Publicado: (2016)